venetoclax,daratumumab,cytarabine,teclistamab,quizartinib
genmab,janssen,Abbvie,roche
['majestec-1', 'daratumumab', 'multiple myeloma']
indirect comparison of teclistimab in majestec-1 versus physician s choice of therapy in long-term follow-up of triple-class exposed relapsed/refractory multiple myeloma in daratumumab trials (p972) #eha2022 
Professor of hematology, Universitary hospital of Sidi Bel Abbés.
Head, Hospitalisation and  Geriatric Unit.